Also known as MGH and The General Hospital Corporation.
Clinical, long-term and real‑world data show deeper ocular MG responses, one‑year efficacy in AChR‑Ab–negative MG, benefits of earlier treatment, CIDP durability and pipeline progress.
Partners will create an integrated translational platform to quantify mechanisms, pathways and kinetics of nose-to-brain drug transport using in vitro, in vivo and computational tools.
FDA cleared therapy for wAIHA in patients ≥12 previously or currently treated with corticosteroids; showed rapid hemoglobin gains and durable responses in Phase 2/3 ENERGY.
